Source: GlobalNewswire

OSE Immunotherapeutics received $9.1M in Grant Funding

Read full article »

OSE Immunotherapeutics's Competitors | OSE Immunotherapeutics's News | OSE Immunotherapeutics's Financials

Followers on Owler

Annual Revenue

$5.0-25M

Employees

25-100

CEO

Nicolas Poirier

CEO Approval Rating

87/100

OSE Immunotherapeutics is a France-based biotechnology company that researches and develops immunotherapies for the treatment of cancer and autoimmune diseases.